Stein annexstad

Biography

 Mr. Stein Holst Annexstad has served as Independent Chairman of the Board at BERGENBIO ASA since January 16, 2017. He has been Non-Executive Director of the Company since February 1, 2016. Mr. Annexstad holds a BA in Commerce from the Norwegian School of Economics (1969). He has senior industry experience, both at executive and Board levels. He is former executive of Dyno Industrier AS (fine chemicals), and became the CEO of the pharmaceutical firm Nycomed AS (subsequently merged with Amersham Plc and thereafter merged with GE). He was head of AS Isco Group, an Executive Search and Corporate Advisory Group. Mr. Annexstad was in 1996 a co-founder of NorgesInvestor AS, an Oslo-based Private Equity firm, and was in 2008 the first Chairman of Investinor AS (the VC of the Norwegian State). At the same time he was Chairman of Algeta ASA, the pharmaceutical startup that successfully developed Xofigo (prostate cancer drug) and was acquired by Bayer Health Care in 2014. His other previous chairman positions comprise commercial banking, business school, public R&D and various industrial enterprises. He currently servesat VEAS-Vestfjorden Avlopsselskap (chairman), Asker Kommunale Pensjonskasse (board member) and Holstein AS (managing director and board member). Previously, he was employed at Algeta ASA (chairman), Investinor AS (chairman), Biomedisinsk Innovasjon AS (board member), Norsk Medisinsk Syklotronsenter AS (chairman), Agenda Kaupang AS (chairman) and Biotec Pharmacon ASA (chairman of the nominations committee).

Research Interest

 Pharmaceutical